What was Gilead's revenue in Q1 2026?

Gilead's revenue reached $6.7 billion in Q1 2026, beating expectations.

Which new HIV drug received FDA priority review?

The new HIV drug lenacapavir received FDA priority review, potentially accelerating approval.

Why did Gilead's stock fall despite strong results?

The stock fell 7.29% over 30 days due to investor concerns over acquisition-related charges impacting earnings.

What is Gilead's guidance for 2026?

Gilead expects annual revenue of $26-27 billion but anticipates a larger net loss due to acquisition charges.

Gilead Q1 2026 Earnings Beat Estimates; HIV Drug Gets Priority Review

Gilead Sciences (GILD) reported Q1 2026 results that beat analyst expectations, with revenue of $6.7 billion. The company also received FDA priority review for a new HIV regimen, boosting its pipeline outlook.

Gilead Sciences (GILD) reported first-quarter 2026 results that surpassed analyst estimates, with revenue reaching $6.7 billion. The company also announced that its new HIV regimen has been granted priority review by the U.S. Food and Drug Administration (FDA). Despite these positive developments, the stock has declined 7.29% over the past 30 days.

Key Financial Results

Metric	Q1 2026	YoY Change
Revenue	$6.7 billion	+12%
Net Income	$2.1 billion	+8%
EPS	$1.45	+10%

Highlights from the Report

The company attributed the strong performance to growth in core HIV treatment sales and increased demand for liver disease therapies. Additionally, the FDA granted priority review for its new HIV drug lenacapavir, potentially accelerating approval.

Guidance

Gilead revised its full-year 2026 guidance, now expecting a larger net loss due to acquisition-related charges. However, it maintains revenue guidance of $26-27 billion.

Stock Impact

GILD shares fell 7.29% over the past month, likely due to investor concerns over earnings dilution from acquisition costs. However, the underlying business remains robust.

What This Means for Investors

Gilead has strong fundamentals and a diversified product portfolio. The FDA priority review for its HIV drug could be a positive catalyst, but investors should monitor the impact of acquisition charges on future earnings.